Anti-obesity drug benefits 'no longer outweigh risks'

Acomplia's European marketing authorisation for obese and overweight people has been suspended by the European Medicines Agency (EMEA).

The EMEA said it has decided that the benefits of rimonabant, which is marketed in Europe as Acomplia, no longer outweigh its risks. Prescribers should not issue any prescriptions for Acomplia and should review the treatment of patients currently taking the medicine, the EMEA said.

There is no need for patients to stop treatment with Acomplia immediately, but patients who wish to stop can do so at any time, the EMEA advised. Patients who are currently taking Acomplia should consult their doctor or pharmacist at a convenient time to discuss their treatment.

Acomplia's manufacturer Sanofi-Aventis said that it was complying with the EMEA’s recommendation.

‘Sanofi-Aventis is committed to provide additional evidence for the re-evaluation of the benefit/risk profile of Acomplia in patients with diabetes and cardiovascular disease through the ongoing clinical studies,’ the company said in a statement.

‘Sanofi-Aventis remains committed to Acomplia to bring an important therapeutic approach to obese and overweight patients.’

The EMEA said it had assessed the benefits and risks of Acomplia, including data from studies completed since the drug was licensed. These showed an increased risk of psychiatric disorders patients taking Acomplia.

The EMEA said it believed that these side effects could not be adequately addressed by risk minimisation measures.

In addition, the agency said that the effectiveness of Acomplia in clinical practice had been found to be more limited than was expected on the basis of the clinical trials because available data indicate that patients generally take Acomplia
only for a short period.

Comment below and tell us what you think

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins


Already registered?

Sign in

Just published

Practice nurse with patient

Patient safety fears as one in three practice nurses near retirement

General practice is facing a nurse retirement timebomb, with more than a third of...

A&E entrance

Hospitals warn of rising flu admissions and A&E pressures

Hospitals in England have warned that the number of patients being admitted for flu...

Woman on a phone call while using a computer

How the GMC's updated Good Medical Practice applies in real life

MDU medico-legal adviser Dr Ellie Mein looks at how the GMC’s updated guidance would...

Talking General Practice logo

Podcast: Where next for the GP contract, plus Labour’s plan for neighbourhood health centres

Talking General Practice looks at what the BMA's might be looking to achieve in negotiations...


More than 2,000 GP practices switch to registering patients online

More than 2,000 GP practices have signed up to accept patient registrations via an...

Police car

One in eight GPs forced to call police over abusive patients

One in eight GPs have had to call the police to handle an abusive patient in the...